AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21067350
Drug: ceftriaxone 1
RxNorm normalized name: ceftriaxone 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ceftriaxone 1 g every 24 h for 5-7 days
Trial: 12394436
Drug: Stapled rectal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Stapled rectal mucosectomy
Trial: 2247767
Drug: Control (conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (conventional antihypertensive treatment)
Trial: 28605207
Drug: Pain Neurophysiology
RxNorm normalized name: Dermoplast Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pain Neurophysiology Education (PNE) treatment
Trial: 26842122
Drug: Isoproterenol (ISO-stress)
RxNorm normalized name: isoproterenol sulfate Metered Dose Inhaler [Medihaler-Iso]
DrugBank: Isoprenaline (DB01064)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoproterenol (ISO-stress) infusion
Trial: 19647866
Drug: Raltegravir (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltegravir (400 mg oral twice daily)
Trial: 19647866
Drug: Efavirenz (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efavirenz (600 mg oral once daily)
Trial: 8519719
Drug: Bupivacaine 0.25%
RxNorm normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.25% infused at a rate of 5 mL/h
Trial: 8519719
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no bupivacaine infusion)
Trial: 2226911
Drug: Cyclic regimen
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic regimen of 0.625 mg/d of conjugated equine estrogens for 25 days/month and 10 mg medroxyprogesterone acetate for the last 13 days of E
Trial: 2226911
Drug: Continuous regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous regimen of 0.625 mg/d of conjugated equine estrogens along with 5 mg medroxyprogesterone acetate
Trial: 2226911
Drug: Continuous regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous regimen of 0.625 mg/d of conjugated equine estrogens along with 10 mg medroxyprogesterone acetate
Trial: 27405596
Drug: Convalescent plasma
RxNorm normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Convalescent plasma therapy for MERS-CoV infection
Trial: 23319466
Drug: Mean daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mean daily counts per minute (CPM)
Trial: 23319466
Drug: Mean daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mean daily steps per day
Trial: 22561385
Drug: Ultrasonography-guided corticosteroid
RxNorm normalized name: abiraterone and corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasonography-guided corticosteroid injections
Trial: 22561385
Drug: Blind corticosteroid
RxNorm normalized name: Io-Blend
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blind corticosteroid injections
Trial: 18051910
Drug: SCTXLC 0.26
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCTXLC 0.26 g (4 capsules, three times a day) for 28 days
Trial: 18051910
Drug: CCTXLC 0.38
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCTXLC 0.38 g (4 capsules, three times a day) for 28 days
Trial: 12042618
Drug: Intragraft 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intragraft 200 µg verapamil
Trial: 7876926
Drug: Intravenous nutrient
RxNorm normalized name: Votrient
DrugBank: Pazopanib (DB06589)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous nutrient mixture
Trial: 7876926
Drug: Intravenous nutrients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous nutrients
Trial: 350512
Drug: Tolamolol 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolamolol 50 mg
Trial: 6896183
Drug: Tolamolol 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolamolol 100 mg
Trial: 22140497
Drug: verum (local
FDA approved: no
EMA approved: no
PMDA approved: no
Description: verum (local anaesthetic) injection
Trial: 22140497
Drug: placebo (sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo (sodium chloride) injection
Trial: 16860174
Drug: NA/EE 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NA/EE 0.5 mg/2.5 μg
Trial: 7692110
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg finasteride
Trial: 7512661
Drug: Extension study
RxNorm normalized name: EXTENSION TUBES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extension study (5 mg finasteride for all patients)
Trial: 29402767
Drug: Bardoxolone methyl
RxNorm normalized name: Bardoxolone methyl
DrugBank: Bardoxolone methyl (DB05983)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bardoxolone methyl (20 mg once daily)
Trial: 18425402
Drug: Hydrochlorothiazide 12.5
RxNorm normalized name: hydrochlorothiazide 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide 12.5 or 25 mg/day
Trial: 7380205
Drug: Spironolactone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone (200 mg/day)
Trial: 10792338
Drug: Cyproterone acetate
RxNorm normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyproterone acetate (CPA) (50 mg/day) with ethinyl oestradiol (35 microgram/day)
Trial: 6895140
Drug: antirheumatic drugs
RxNorm normalized name: Quinolines, antirheumatic drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: antirheumatic drugs
Trial: 26658900
Drug: High phenolic
RxNorm normalized name: Phenol
DrugBank: Phenol (DB03255)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High phenolic content olive oil (HPC) - 366 mg/kg
Trial: 26658900
Drug: Low phenolic
RxNorm normalized name: Phenol
DrugBank: Phenol (DB03255)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low phenolic content olive oil (LPC) - 2.7 mg/kg
Trial: 23751152
Drug: Sublingual 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual 400 μg misoprostol and 100 mg diclofenac
Trial: 17652452
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg diclofenac alone (control group)
Trial: 15080356
Drug: Submucosal midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Submucosal midazolam (0.2 mg/kg) and oral chloral hydrate (50 mg/kg)
Trial: 15080356
Drug: Oral chloral
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral chloral hydrate (50 mg/kg) and submucosal saline placebo
Trial: 31743165
Drug: Methylprednisolone (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (250 mg IV, 2 doses)
Trial: 28460864
Drug: Natural history
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural history group (no therapy)
Trial: 19925567
Drug: Sertaconazole cream
RxNorm normalized name: sertaconazole Topical Cream
DrugBank: Sertaconazole (DB01153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sertaconazole cream (2%) applied topically twice daily for 2 weeks
Trial: 19925567
Drug: Miconazole cream
RxNorm normalized name: Miconazole Nitrate 2% Topical application Cream [CAREALL MICONAZOLE CREAM]
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Miconazole cream (2%) applied topically twice daily for 2 weeks
Trial: 18697865
Drug: E2 supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2 supplementation (transdermal for 3 weeks)
Trial: 18697865
Drug: Pilot iv
RxNorm normalized name: Picot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pilot iv bolus ghrelin infusions
Trial: 14556812
Drug: Tamoxifen citrate
RxNorm normalized name: Tamoxifen Citrate
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamoxifen citrate 20 mg/d and testosterone undecanoate 120 mg/d (n = 106)
Trial: 14556812
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (n = 106)
Trial: 14556812
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment group (n = 106)
Trial: 3966649
Drug: 30 ml
RxNorm normalized name: Vial M/T 30 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 ml of 0.3 molar sodium citrate less than 60 min preoperatively (n = 11)
Trial: 3966649
Drug: 30 ml
RxNorm normalized name: Vial M/T 30 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 ml of 0.3 molar sodium citrate longer than 60 min preoperatively (n = 11)
Trial: 3966649
Drug: No antacid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antacid (control group, n = 10)
Trial: 27183035
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy (2 times per week for 6 weeks, followed by 6 weeks of monitored home exercise)
Trial: 17096501
Drug: Intra-articular hyaluronic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular hyaluronic acid (HA) injection
Trial: 5443056
Drug: Silastic vaginal
RxNorm normalized name: CATHETER SILASTIC 14FR 5CC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silastic vaginal ring without medication (Control)
Trial: 30985624
Drug: Hybrid treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hybrid treatment (n=58, 10-16 sessions)
Trial: 30985624
Drug: iCBT (n=57;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iCBT (n=57; 8 treatment modules)
Trial: 21355444
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of pioglitazone 45 mg
Trial: 21355444
Drug: Reference product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference product of pioglitazone 45 mg
Trial: 19954060
Drug: mRNA expression
RxNorm normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 Injectable Suspension [Spikevax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA expression of functional genes of neutrophils, monophagocytes, IFN regulating factors, TNF, adhesion molecules and T cells in PE patients
Trial: 10834777
Drug: Bupivacaine 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 8 mg + Fentanyl 10 microg
Trial: 10834777
Drug: Bupivacaine 10
RxNorm normalized name: BUPivacaine 100 mg parenteral implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 10 mg + Fentanyl 10 microg
Trial: 10834777
Drug: Bupivacaine 12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 12 mg
Trial: 10834777
Drug: Bupivacaine 12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 12 mg + Fentanyl 10 microg
Trial: 7681510
Drug: Felodipine after
RxNorm normalized name: Felodipine
DrugBank: Felodipine (DB01023)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Felodipine after 1 week of oral ramipril
Trial: 3092654
Drug: Ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine 150 mg intragastrically
Trial: 31721089
Drug: Cinnamon capsules
DrugBank: Cinnamon (DB10520)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinnamon capsules for 60 days
Trial: 31721089
Drug: Orlistat twice
RxNorm normalized name: Orlistat
DrugBank: Orlistat (DB01083)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Orlistat twice daily for 30 days, then once daily for another 30 days
Trial: 18404296
Drug: Preoperative decolonization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative decolonization protocol using mupirocin ointment (twice daily) and chlorhexidine bath (once daily) for 5 days before surgery.
Trial: 18404296
Drug: Concurrent control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent control group (patients of surgeons who did not participate in the intervention study).
Trial: 28543183
Drug: Esomeprazole (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole (40 mg)
Trial: 7857114
Drug: Jessner's solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jessner's solution and 35% trichloroacetic acid (single application)
Trial: 7857114
Drug: 5% fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% fluorouracil cream (twice daily applications for 3 weeks)
Trial: 7112797
Drug: Nitrofurantoin macrocrystals
RxNorm normalized name: Nitrofurantoin Macrocrystals
DrugBank: Nitrofurantoin (DB00698)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitrofurantoin macrocrystals 200 mg daily
Trial: 27859478
Drug: Traditional oral
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional oral motor exercises (Control)
Trial: 26255012
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin sodium (LMWHS) 2,500 U subcutaneously, twice a day for 5 days
Trial: 26255012
Drug: Heparin sodium
RxNorm normalized name: Heparin Sodium
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Heparin sodium 12,500 U intravenously for 24 hours for 5 days
Trial: 23140479
Drug: Masked Gabor
RxNorm normalized name: MASK
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Masked Gabor patches presented in the fovea
Trial: 23140479
Drug: Masked Gabor
RxNorm normalized name: MASK
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Masked Gabor patches presented in near periphery (6°)
Trial: 15545163
Drug: OMC (ome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OMC (ome 20 mg b.i.d., metronidazole 400 mg b.i.d., clarithromycin 250 mg b.i.d.)
Trial: 15545163
Drug: OP (ome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OP (ome 20 mg and placebo)
Trial: 15545163
Drug: OMC (ome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OMC (ome 20 mg b.i.d., metronidazole 400 mg b.i.d., clarithromycin 250 mg b.i.d.) with NSAIDs
Trial: 15545163
Drug: OP (ome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OP (ome 20 mg and placebo) with NSAIDs
Trial: 12577391
Drug: Acanthopanax senticosus
RxNorm normalized name: Acanthopanax Senticosus (Eleuthero) Root
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acanthopanax senticosus (AS) treatment
Trial: 8400346
Drug: octreotide 0.5
RxNorm normalized name: octreotide 0.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: octreotide 0.5 mg three times per day s.c.
Trial: 8400346
Drug: loperamide 4
RxNorm normalized name: loperamide 0.4 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: loperamide 4 mg three times per day p.o.
Trial: 2439781
Drug: Placebo (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (after discontinuation of active treatment)
Trial: 2439781
Drug: All doses
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All doses of bisoprolol (5, 10, 20 mg)
Trial: 2439781
Drug: All doses
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All doses of bisoprolol
Trial: 29540325
Drug: SGLT-2 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SGLT-2 inhibitors (SGLT-2i)
Trial: 18984667
Drug: Pioglitazone 45
RxNorm normalized name: pioglitazone 45 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone 45 mg daily for 6 months
Trial: 21169260
Drug: CAF (Cyclophosphamide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAF (Cyclophosphamide, intravenous doxorubicin, and 5-fluorouracil)
Trial: 21169260
Drug: CMF (Cyclophosphamide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMF (Cyclophosphamide, intravenous methotrexate, and 5-fluorouracil) ± tamoxifen
Trial: 12690224
Drug: Caffeine 6
RxNorm normalized name: caffeine 65 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 6 mg/kg plus ethanol 0.2 g/kg
Trial: 12690224
Drug: Caffeine 8
RxNorm normalized name: caffeine 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 8 mg/kg plus ethanol 0.4 g/kg
Trial: 12690224
Drug: Concomitant thrombolytic
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant thrombolytic therapy
Trial: 10663449
Drug: 1.25 mg
RxNorm normalized name: menthol 1.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 mg intravenous glibenclamide (Gb)
Trial: 1531219
Drug: 2g/m2 of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2g/m2 of etanidazole administered intravenously after 30 min (group A)
Trial: 1531219
Drug: 2g/m2 of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2g/m2 of etanidazole administered intravenously after 60 min (group B)
Trial: 1531219
Drug: 2g/m2 of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2g/m2 of etanidazole administered intravenously after 120 min (group C)
Trial: 27839981
Drug: Taliglucerase alfa
RxNorm normalized name: Taliglucerase alfa
DrugBank: Taliglucerase alfa (DB08876)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Taliglucerase alfa (dose as previously treated with imiglucerase)
Trial: 26869678
Drug: PRM‐151 (recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRM‐151 (recombinant human pentraxin‐2) at doses of 1, 5, or 10 mg·kg(‐1) administered intravenously on days 1, 3, 5, 8, and 15.
Trial: 24462229
Drug: Cognitive-behavioral group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral group therapy (CBT-arm)
Trial: 24462229
Drug: Ultra-brief pulse
RxNorm normalized name: BRIEF,ULTRA BRIEF LARGE TENA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultra-brief pulse continuation electroconvulsive therapy (ECT-arm)
Trial: 24462229
Drug: No add-on
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No add-on therapy (MED-arm)
Trial: 22823477
Drug: Screening and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Screening and promotion of target-driven, intensive treatment of multiple risk factors (n = 1678 patients)
Trial: 17825197
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment combined with laparoscopy and digital subtraction angiography (group B)
Trial: 12088807
Drug: Sodium thiopental,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium thiopental, 5 mg/kg (25 microg/kg/min)
Trial: 12088807
Drug: Generic propofol,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic propofol, 1.25 mg/kg (50 microg/kg/min)
Trial: 12088807
Drug: Nongeneric propofol,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nongeneric propofol, 1.25 mg/kg (50 microg/kg/min)
Trial: 8132701
Drug: Coumarin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coumarin (50 mg daily for 2 years)
Trial: 2510561
Drug: 0.1 mg
RxNorm normalized name: biotin 0.1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg intravenous flumazenil repeated every minute until fully awake (mean 4.5 +/- 2.6 micrograms.kg‐1)
Trial: 28568608
Drug: Flibanserin 100
RxNorm normalized name: flibanserin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flibanserin 100 mg at bedtime (acute dose)
Trial: 28568608
Drug: Flibanserin 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flibanserin 200 mg after chronic dosing (supratherapeutic dose)
Trial: 28568608
Drug: Zopiclone 7.5
RxNorm normalized name: zopiclone 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zopiclone 7.5 mg (positive control)
Trial: 21272154
Drug: Tolterodine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolterodine treatment for 6 months
Trial: 19151286
Drug: 3 mL
RxNorm normalized name: WATER,INHL 3 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mL of lidocaine 15 mg/mL with epinephrine 5 microg/mL
Trial: 2678804
Drug: Ca Heparin
RxNorm normalized name: heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ca Heparin (0.5 mgs b.i.b.) + EC
Trial: 2678804
Drug: Venoruton (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venoruton (1 g, t.i.d.) + EC
Trial: 2678804
Drug: Venoruton (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venoruton (1 g, t.i.d.) after superficial thrombectomy + EC
Trial: 17988379
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (TA) 2 g before and after intervention
Trial: 9388128
Drug: 20-mg lovastatin
RxNorm normalized name: lovastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20-mg lovastatin for 6 months
Trial: 31232840
Drug: Standard occlusive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard occlusive dressing method (hydrogel or alginate and hydrocolloid compounds)
Trial: 23380428
Drug: Tizanidine PIC®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tizanidine PIC® 4 mg
Trial: 23380428
Drug: Sirdalud® 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirdalud® 4 mg
Trial: 16941685
Drug: Peginterferon alpha-2b
RxNorm normalized name: ROPEGINTERFERON ALPHA-2B-NJFT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peginterferon alpha-2b (1.5 microg/kg) monotherapy
Trial: 16941685
Drug: Peginterferon alpha-2b
RxNorm normalized name: ROPEGINTERFERON ALPHA-2B-NJFT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peginterferon alpha-2b (1.5 microg/kg) in combination with ribavirin
Trial: 14613633
Drug: Topical ivermectin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ivermectin (lotion)
Trial: 14613633
Drug: Thiabendazole (ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiabendazole (ointment and lotion)
Trial: 14613633
Drug: Metrifonate (lotion)
RxNorm normalized name: Metrifonate
DrugBank: Metrifonate (DB11473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metrifonate (lotion)